New Eczema Ointment Eases Itch in One Week
Adults and children with mild to moderate atopic dermatitis saw improvement in severity and itch within a week in trials of difamilast 1%.
Updated on Nov. 2, 2026 in Asthma
Difamilast 1% ointment improved disease severity and itch within one week in pooled phase 2 and 3 trials of adults and children with mild to moderate atopic dermatitis. The pooled program data were presented at the 2026 Fall Clinical Dermatology Conference in Las Vegas, Nevada, and the FDA approved the drug in February 2026 for patients aged 2 years and older.
Why it matters
Atopic dermatitis is a common, chronic inflammatory skin condition, and new topical options add to the choices available for managing flares in people with mild to moderate disease. The data suggest early symptom relief, though the trials were short-term and results come from company-presented program data.
Data from a phase 2 trial of 121 individuals aged 10 to 70 and two phase 3 trials (365 adolescents and adults, and 251 children aged 2 to 14) compared difamilast 1% ointment with vehicle over 4 to 8 weeks. In the adult trial, 38.46% of treated patients achieved IGA success at week 4 versus 12.64% on vehicle; the pediatric trial showed 47.1% versus 18.1%. Longer-term outcomes beyond these short treatment windows remain unreported in this data set.
The players
U.S. Food and Drug Administration (FDA)
The U.S. agency that regulates prescription drugs and approved difamilast for atopic dermatitis in February 2026.
The details
Difamilast is a topical phosphodiesterase-4 (PDE4) inhibitor, a class of drugs that works inside skin cells to dampen inflammatory signaling associated with eczema. Applied directly to affected skin, it targets local inflammation rather than acting systemically. In the trials, its effects were measured with Investigator's Global Assessment (IGA), the Eczema Area and Severity Index (EASI), itch scores, and patient-reported outcomes. Across the clinical program, no clinically meaningful gastrointestinal safety signals, including diarrhea, were observed.
Timeline
February 2026: FDA approved difamilast for patients aged 2 years and older with mild to moderate atopic dermatitis.
2026 Fall Clinical Dermatology Conference: pooled program data were presented in Las Vegas, Nevada.
Health Landscape
Difamilast joins the topical PDE4-inhibitor class established by crisaborole, giving clinicians another non-steroidal ointment alongside traditional corticosteroids. Non-steroidal options matter because long-term topical steroid use carries local side effects, so expanding the toolkit for mild to moderate disease is a meaningful shift in the treatment landscape.
If you have mild to moderate eczema, this data suggests a topical option may begin easing itch and skin inflammation within the first week, which is worth raising with your dermatologist. Because the evidence comes from short trials, discuss with your doctor whether a newer ointment fits your situation alongside your current care plan.
The takeaway
Early itch and severity improvement with a non-steroidal topical option is a promising development for mild to moderate atopic dermatitis. Ask your dermatologist whether a topical PDE4 inhibitor could be appropriate for your skin, and track flare patterns to bring to your visit.
Further reading
For broader context on allergic and inflammatory conditions, explore our Asthma coverage.
